How frequently is Romosozumab-AQQP (Evenity) administered?

• A. Weekly for 6 months
• B. Daily for 12 months
• C. Once monthly for 12 months
• D. Every three months

Answer: (C)

Romosozumab-AQQP, marketed as Evenity, is a medication used for the treatment of osteoporosis in postmenopausal women at high risk of fracture. The dosing schedule for this medication is specifically designed to maximize its therapeutic potential while minimizing any safety concerns.

The correct answer reflects that Romosozumab is administered once monthly for 12 months. This regimen is established to ensure that patients receive a consistent dose that effectively increases bone density and reduces the risk of fractures over a significant period. The monthly administration helps maintain stable drug levels in the body, which is crucial for its intended effects on bone remodeling and strength.

Furthermore, this monthly schedule allows healthcare providers to monitor patients effectively and manage any potential side effects that could arise from treatment. Understanding this dosing frequency is essential for healthcare professionals in managing osteoporosis therapies, as it helps in planning treatment itineraries and reinforcing adherence among patients.